药物与临床
LI Liang;YANG Jianhong;DAI Xiongkai;SU Wei
2012, 31(9): 1150-1153.
ABSTRACT Objective To investigate the efficacy and safety of paliperidone in treating acute schizophrenia.MethodsEighty patients with acute schizophrenia were randomly assigned to the test group (paliperidone,n=40) and control group (ziprasidone,n=40),who were administrated with paliperidone and ziprasidone,respectively,and were studied for 8 weeks.The clinical efficacy was evaluated with the Positive and Negative Syndrome Scale (PANSS) before and 1,2,4,8 weeks after treatment.Side effects were assessed with the Treatment Emergent Symptom Scale (TESS).ResultsThe total score of PANSS and each point in the two groups were notably decreased (P<0.01) after treatment compared with that before treated.The total scores of PANSS and positive symptoms in the treatment group were significantly better than those in the control by the end of the 1st and 2nd weekends (P<0.05).The effective rate of the two groups was 67.5% and 65.0 %,respectively (P>0.05).The serum prolactin level in the test group was increased significantly after treatment (P<0.01), while which exhibited no significant change in the control group and there was significant difference between two groups.The incidence of abnormal liver function in treatment group was obviously lower than that in the control group (P<0.05).There were no severity adverse effects in both groups.ConclusionPaliperidone shows reliable clinical efficacy,quick effect and safety for treating acute schizophrenia.